No Picture
News

STAT+: Pharmalittle: Biogen CEO admits Alzheimer’s drug price was ‘wrong’; Becerra orders HHS to reconsider Medicare premium hike

Biogen CEO Michel Vounatsos acknowledged Monday that the company was “wrong” to initially price its Alzheimer’s treatment at $56,000 a year. Click here to view original post… […]

No Picture
News

STAT+: Pharmalittle: Pfizer makes a major push into mRNA technology; Medicare decision on Alzheimer’s drug may hurt state budgets

A preliminary decision on Medicare coverage for the Biogen Alzheimer’s drug is due this week, and it has major implications for state Medicaid programs. Click here to view original post… […]

No Picture
News

STAT+: Pharmalittle: More top hospitals aren’t offering Biogen Alzheimer’s drug; Pfizer may lower Covid pill price in poor countries until supplies rise

The organization that negotiates supply contracts on behalf of more than 95% of the nation’s academic hospitals estimates just one to five vials of the Biogen Alzheimer’s medicine are ordered… Click here to view original post… […]